Premium
Serum WFA + ‐M2BP levels as a prognostic factor in patients with early hepatocellular carcinoma undergoing curative resection
Author(s) -
Toyoda Hidenori,
Kumada Takashi,
Tada Toshifumi,
Kaneoka Yuji,
Maeda Atsuyuki,
Korenaga Masaaki,
Mizokami Masashi,
Narimatsu Hisashi
Publication year - 2016
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/liv.12907
Subject(s) - hepatocellular carcinoma , medicine , gastroenterology , hepatectomy , liver function , stage (stratigraphy) , pathology , resection , biology , surgery , paleontology
Background & Aims Serum tumour markers for hepatocellular carcinoma ( HCC ) have less prognostic significance in early stage. Serum Wisteria floribunda agglutinin‐positive Mac‐2‐binding protein (WFA + ‐M2BP) levels are reportedly associated with hepatocarcinogenic potential in patients with chronic liver diseases. We investigated the prognostic significance of pretreatment serum WFA + ‐M2BP levels in patients with early‐stage HCC . Methods A total of 240 patients who underwent hepatic resection for naïve Barcelona Clinic Liver Cancer ( BCLC ) class 0 or A HCC were analysed. WFA + ‐M2 BP and tumour markers for HCC were measured from serum obtained just prior to treatment. Post‐operative recurrence and survival rates were compared according to these serum markers, tumour stage and Child–Pugh class. Results There was an association between serum WFA + ‐M2 BP levels and the fibrosis grade of resected noncancerous liver tissue, whereas no association was found between WFA + ‐M2 BP levels and tumour progression or liver function. In a multivariate analysis, pretreatment serum WFA + ‐M2 BP level was associated with recurrence and survival, respectively, independent of HCC progression or fibrosis grade of resected noncancerous liver tissue. Recurrence rates after hepatic resection were significantly higher in patients with a pretreatment serum WFA + ‐M2 BP ≥ 3.00 than those with a pretreatment serum WFA + ‐M2 BP < 3.00 ( P = 0.0038). Survival rates were lower in patients with a pretreatment serum WFA + ‐M2 BP ≥ 3.00 than those with a pretreatment serum WFA + ‐M2 BP < 3.00 ( P = 0.0187). Conclusions Serum WFA + ‐M2 BP level is a prognostic factor for recurrence and survival, in addition to tumour progression and liver function, in patients with early‐stage HCC treated with curative hepatic resection.